Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long(The University of Sydney), Dirk Schadendorf(National Center for Tumor Diseases), Uwe Trefzer(Goethe University Frankfurt), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Julie Switzky(GlaxoSmithKline (United States)), Axel Hauschild(University Hospital Schleswig-Holstein), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Mary Guckert(GlaxoSmithKline (United States)), Richard Kefford(Broad Institute), Lisa Zimmer(The University of Sydney), Alain P. Algazi(University of California, San Francisco), Tabea Wilhelm(Charité - Universitätsmedizin Berlin), Laurent Mortier, Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Caroline Robert(Institut Gustave Roussy), Michael Streit(GlaxoSmithKline (United States)), S. Swann(GlaxoSmithKline (United States)), Anne-Marie Martin(GlaxoSmithKline (United States)), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Vicki Goodman, John M. Kirkwood(UPMC Hillman Cancer Center)
Cited by 906
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k